vs
Indivior Pharmaceuticals, Inc.（INDV）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Indivior Pharmaceuticals, Inc.的1.7倍（$622.0M vs $357.0M），Royalty Pharma plc净利率更高（34.4% vs 28.9%，领先5.6%）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
INDV vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$357.0M
净利率更高
RPRX
高出5.6%
28.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $622.0M |
| 净利润 | $103.0M | $214.2M |
| 毛利率 | 82.1% | — |
| 营业利润率 | 22.7% | 62.4% |
| 净利率 | 28.9% | 34.4% |
| 营收同比 | — | 4.8% |
| 净利润同比 | 390.5% | 2.9% |
| 每股收益（稀释后） | $0.79 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVRPRX
| Q4 25 | $357.0M | $622.0M | ||
| Q3 25 | $314.0M | $609.3M | ||
| Q2 25 | $302.0M | $578.7M | ||
| Q1 25 | $266.0M | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | $307.0M | $564.7M | ||
| Q2 24 | $299.0M | $537.3M | ||
| Q1 24 | — | $568.0M |
净利润INDVRPRX
| Q4 25 | $103.0M | $214.2M | ||
| Q3 25 | $42.0M | $288.2M | ||
| Q2 25 | $18.0M | $30.2M | ||
| Q1 25 | $47.0M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $22.0M | $544.0M | ||
| Q2 24 | $-97.0M | $102.0M | ||
| Q1 24 | — | $4.8M |
毛利率INDVRPRX
| Q4 25 | 82.1% | — | ||
| Q3 25 | 73.2% | — | ||
| Q2 25 | 82.8% | — | ||
| Q1 25 | 83.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 78.5% | — | ||
| Q2 24 | 73.6% | — | ||
| Q1 24 | — | — |
营业利润率INDVRPRX
| Q4 25 | 22.7% | 62.4% | ||
| Q3 25 | 13.7% | 70.1% | ||
| Q2 25 | 23.8% | 36.3% | ||
| Q1 25 | 24.8% | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -39.5% | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率INDVRPRX
| Q4 25 | 28.9% | 34.4% | ||
| Q3 25 | 13.4% | 47.3% | ||
| Q2 25 | 6.0% | 5.2% | ||
| Q1 25 | 17.7% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 7.2% | 96.3% | ||
| Q2 24 | -32.4% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益（稀释后）INDVRPRX
| Q4 25 | $0.79 | $0.49 | ||
| Q3 25 | $0.33 | $0.67 | ||
| Q2 25 | $0.14 | $0.07 | ||
| Q1 25 | $0.38 | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $0.16 | $1.21 | ||
| Q2 24 | $-0.72 | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $-98.0M | $9.7B |
| 总资产 | $1.2B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资INDVRPRX
| Q4 25 | $195.0M | $618.7M | ||
| Q3 25 | $445.0M | $938.9M | ||
| Q2 25 | $510.0M | $631.9M | ||
| Q1 25 | $373.0M | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务INDVRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益INDVRPRX
| Q4 25 | $-98.0M | $9.7B | ||
| Q3 25 | $-207.0M | $9.6B | ||
| Q2 25 | $-257.0M | $9.5B | ||
| Q1 25 | $-285.0M | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | $-310.0M | $10.3B | ||
| Q2 24 | $-281.0M | $9.8B | ||
| Q1 24 | — | $9.9B |
总资产INDVRPRX
| Q4 25 | $1.2B | $19.6B | ||
| Q3 25 | $1.4B | $19.3B | ||
| Q2 25 | $1.5B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | — | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比INDVRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | — |
| 自由现金流率自由现金流/营收 | -68.6% | — |
| 资本支出强度资本支出/营收 | 6.7% | — |
| 现金转化率经营现金流/净利润 | -2.15× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-93.0M | — |
8季度趋势，按日历期对齐
经营现金流INDVRPRX
| Q4 25 | $-221.0M | $827.1M | ||
| Q3 25 | $-39.0M | $702.6M | ||
| Q2 25 | $158.0M | $364.0M | ||
| Q1 25 | $75.0M | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $2.0M | $703.6M | ||
| Q2 24 | $88.0M | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流INDVRPRX
| Q4 25 | $-245.0M | — | ||
| Q3 25 | $-59.0M | — | ||
| Q2 25 | $141.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.0M | — | ||
| Q2 24 | $84.0M | — | ||
| Q1 24 | — | — |
自由现金流率INDVRPRX
| Q4 25 | -68.6% | — | ||
| Q3 25 | -18.8% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.6% | — | ||
| Q2 24 | 28.1% | — | ||
| Q1 24 | — | — |
资本支出强度INDVRPRX
| Q4 25 | 6.7% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 5.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | — |
现金转化率INDVRPRX
| Q4 25 | -2.15× | 3.86× | ||
| Q3 25 | -0.93× | 2.44× | ||
| Q2 25 | 8.78× | 12.06× | ||
| Q1 25 | 1.60× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 0.09× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
